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Abstract
Background: Preβ1-high-density lipoprotein (preβ1-HDL), plays an important role in reverse cholesterol transport
and exhibits potent risk for coronary artery disease (CAD). However, the association of plasma preβ1-HDL and
cholesterol ester transfer protein (CETP) levels in CAD patients and the relationship of preβ1-HDL with extent of
CAD are debatable.
Methods: Preβ1-HDL and CETP levels were measured by enzymed-linked immunosorbent assay (ELISAs) in 88 acute
coronary syndromes (ACS), 79 stable coronary artery disease (SCAD) patients and 85 control subjects. The correlation
analyses, multiple linear regression analyses and logistic regression analyses were performed, respectively.
Results: The preβ1-HDL and CETP levels in ACS patients were significantly higher than those in SCAD patients and both
of them were higher than controls’. Preβ1-HDL levels were positively associated with CETP (R = 0.348, P = 0.000), the
diameter of stenosis (R = 0.253, P = 0.005), the number of vessel disease (R = 0.274, P = 0.002) and Gensini score (R = 0.227,
P = 0.009) in CAD patients. Stepwise multiple linear regression analyses showed that CETP was one of the determinants of
preβ1-HDL levels. Logistic regression analysis revealed that elevated preβ1-HDL and CETP were potential risk factors for
both ACS and SCAD.
Conclusion: The elevated preβ1-HDL levels may change with CETP concentrations in CAD patients and were related to
the presence and severity of CAD.
Keywords: Preβ1-HDL, CETP, Coronary artery disease, Atherosclerosis
Background
Preβ1-high-density lipoprotein (preβ1-HDL), a quantita-
tively minor high-density lipoprotein (HDL), is formed
as nascent apolipoprotein (apo) A-I enters plasma and
as a substrate or product in interconversion of HDL spe-
cies [1]. After receiving free cholesterol effluxed from
ATP binding cassette transporter A1 (ABCA1) trans-
porter, it is esterified with a free fatty acid derived from
lecithin mediated by lecithin-cholesterol acyl transferase
(LCAT) [2, 3]. Cholesteryl esters (CE) are then incorpo-
rated into cores of α-HDL, subsuming preβ1-HDL. CE
are transferred from α-high-density lipoprotein into
cores of accepter lipoproteins by cholesterol ester trans-
fer protein (CETP) [4]. The preβ1-HDL was shown to be
significantly correlated to the high efflux which was me-
diated by ABCA1 [5]. The fasting preβ1-HDL concentra-
tion has been reported elevated in patients with
coronary artery disease (CAD), hyperlipidemia, type 2
diabetic, obesity and hemodialysis [6–9]. It is proposed
that increased preβ1-HDL may be used as a marker of
risk for structural CAD, myocardial infarction (MI) and
cerebral vascular disease (CVD) [10]. However, a recent
study reported that serum preβ1-HDL levels detected by
their new one-dimensional polyacrylamide gel electro-
phoresis (PAGE) system were negatively associated with
severity of CAD [11]. This result needs further
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validition. Actually, the relationship between preβ1-HDL
and CAD is still controversial.
CETP, one of decisive factors that determines high-
density lipoprotein cholesterol (HDL-C), mediates the
transfer of CE from HDL to low density lipoprotein
(LDL), very low density lipoprotein (VLDL), and an ex-
change of triglyceride (TG). It relates to particle size,
lipid composition and function of lipoprotein [12]. CETP
also plays a key role in reverse cholesterol transport
(RCT) and development of atherosclerosis [13, 14]. Sev-
eral lines of evidence have shown that incubation of
large α-HDL particles with CETP could produce preβ1-
HDL [6, 7]. which suggested the levels of preβ1-HDL
may be associated with CETP. An earlier research per-
formed in transgenic mice indicated that the expression
of CETP resulted in an increase in the proportion of
apoA-I in the preβ1-HDL fraction and a stimulation of
the efflux and esterification of cell-derived cholesterol
[15]. However, study has been published to show the re-
lationship of plasma preβ1-HDL and CETP levels in
CAD patients. Therefore, this study was undertaken to
investigate the associations of plasma preβ1-HDL and
CETP in CAD patients, and to further elucidate the




A total of 167 admitted CAD patients were randomly
enrolled from the Department of Cardiology of Jinling
Hospital between January 2014 and March 2015. All the
patients were undergoing clinically indicated coronary
angiography. Angiograms of all the CAD patients
showed at least 50% stenosis in ≥1 coronary artery. 88
patients with acute coronary syndromes (ACS) included
acute myocardial infarction patients and unstable angina
(UA) with Braunwald classification II or III, who exhib-
ited the positive cardiac biomarkers result [cardiactropo-
nin I (cTnI) > 0.090 ng/ml], acute ischemic-type chest
pain (lasting for > 15 min, duration from symptoms on-
set to emergency admission within 72 h) and character-
istic electrocardiogram changes. 79 stable coronary
artery disease (SCAD) patients with a normal electrocar-
diogram and documented normal left ventricular con-
tractility, except for possible minor nonspecific ST-T
features, had a minimum 1-year history without any car-
diac events/procedures suggestive of ACS. The exclusion
criteria of the CAD patients included mild disease of
angiography (a stenosis of 10 to 50% of the luminal
diameter in all the 3 coronary arteries), prior coronary
revascularization, and the presence of renal disease. 85
control subjects selected from routine health examin-
ation were found normal in physical and electrocardiog-
raphy and laboratory tests, and without diseases such as
hyperlipidemia, hypertension, diabetes mellitus, or any
clinical evident sign of atherosclerosis. In patients with
ACS, blood samples were taken on admission. Blood sam-
ples were collected at least 12 h after fasting from control
subjects and patients with SCAD. The blood sample was
collected into EDTA (1 mg/ml) containing tube and
plasma was promptly separated by a 15 min centrifugation
at 3000 rpm, then stored at −80 °C until analysis. This
study protocol was approved by the Ethics Committee of
Jinling Hospital (REC number: GH23335H) and all the
subjects provided written informed consent.
Angiographic analysis
Catheterization was performed by either the Sones or the
Judkins. Multiple views including angulated views were
obtained, and the angiograms were evaluated. The extent
of angiographically documented CAD was quantified in
the left anterior descending coronary artery, the left cir-
cumflex artery, or the right coronary artery as follows:
normal coronary arteries (smooth, with either no stenosis
or a stenosis of <10% of the luminal diameter), mild dis-
ease (a stenosis of 10 to 50% of the luminal diameter in
one or more coronary arteries), or one-vessel, two-vessel,
or three-vessel disease, defined as a stenosis of more than
50% of the luminal diameter in one, two, or three coron-
ary arteries. To eliminate bias of judgment, angiographic
observation and laboratory assays were conducted by dif-
ferent investigators in a double-blind way until all results
were recorded and ready for statistical analysis. The sever-
ity of CAD was determined according to the Gensini score
based on the degree of luminal stenosis and its geograph-
ical importance [16]. Reductions in the luminal diameter
of 1–25%, 26–50%, 51–75%, 76–90%, 91–99% and total
occlusion were respectively evaluated as 1, 2, 4, 8, 16 and
32. Each principal vascular segment was multiplied by a
factor in accordance with the functional importance of the
myocardial area supplied by that segment, that is, the left
main (LM) was assigned a multiplier × 5; the proximal
segment of the left anterior descending (LAD) and the
proximal segment of the left circumflex (LCX) × 2.5; the
middle of the LAD× 1.5; the distal segment of the LAD,
the right coronary artery (RCA), the posterolateral artery,
and the obtuse marginal artery × 1; and other small vascu-
lar branches × 0.5 [17].
Assays
Preβ1-HDL in human plasma was measured by a com-
mercial preβ1-HDL sandwich enzymed-linked immuno-
sorbent assay (ELISA) kits from Sekisui Medical Co. LTD
as described [18]. CETP was measured by sandwich
ELISA as our laboratory described [19, 20]. TC, TG, high
density lipoprotein (HDL) cholesterol were measured
(Daiichi Pure Chemicals, Japan) on a Hitachi 7600
analyzer. Low-density lipoprotein cholesterol (LDL-C) was
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estimated using the Friedewald formula [21]. Creatine
kinase-MB (CK-MB) was studied with Roche diagnostic
kits in a COBAS C-8000 Roche autoanalyzer and studied
by an immunological UV method, and cardiac troponin I
(cTnI) tests were studied with TOSOH ST AIA-PACK
cTnI 3-rd-Gen kit by AIA-2000ST TOSOH autoanalyzer.
Statistic analysis
Statistic analyses were performed with SPSS 16.0 and
the values were expressed as the mean ± standard devi-
ation (SD). One Sample Kolmogorov-Smirnov Test was
used to evaluate the normality of distribution of the vari-
ables. The skewed data, such as preβ1-HDL, CETP and
TG concentrations were log-transformed to create a
more normal distribution. The differences of variants
among groups were analyzed by one-way analysis of
variance (ANOVA), and the differences between groups
were subsequently determined by Fisher LSD test when
appropriate. The difference in the extent of angiograph-
ically documented disease, cTnI and CK-MB between
two groups was analyzed by Student’s t-test. The differ-
ences in sex among groups and medication were analyzed
by the Chi-square test. Correlations between preβ1-HDL,
CETP, Gensini score, cTnI and other variables in CAD pa-
tients were calculated by the non-parametric Spearman
rank coefficient test. The stepwise multiple linear regres-
sion analyses (Pin = 0.05, Pout = 0.10) were used to identify
the influencing factor for plasma preβ1-HDL levels. The
univariate and multivariate logistic regression analyses
were used to calculate the approximation of the relative
risk, odds ratio (OR) and 95% confidence interval (CI) for
selected variables. A two-tailed P-value less than 0.05 was
considered statistically significant.
Results
Baseline clinical characteristics in the study group
The baseline clinical characteristics of the patients and
control subjects, indications for coronary disease, and
lipid measurements are showed in Table 1. There was
no significant difference in age or sex among the ACS or
SCAD patients and control subjects (P > 0.05). 54.5% of
ACS and 31.6% of SCAD patients received statin treat-
ment in the present study at the time of sampling. The
extent of angiographically documented CAD in the ACS
patients was greater than that in SCAD patients
(Table 1).
Plasma preβ1-HDL, CETP and lipid concentrations in ACS
and SCAD patients
Compared with control subjects, preβ1-HDL and CETP
levels were found significantly increased in both patients
with ACS and SCAD. Furthermore, preβ1-HDL and
CETP levels were significantly higher in ACS than those
in SCAD (Table 2).
Associations among preβ1-HDL, CETP, other lipid levels
and the extent of CAD
To study the relationship of preβ1-HDL, CETP, other lipid
parameters and the extent of CAD, Spearman rank correl-
ation analyses were performed. In all the CAD patients, in-
cluding ACS and SCAD patients, preβ1-HDL were found
positively correlated with CETP (r= 0.348, P = 0.000), max-
imal stenosis (r = 0.253, P = 0.005), number of vessel dis-
ease (r = 0.274, P = 0.002), Gensini score (r = 0.227, P
= 0.009), TC (r= 0.401, P= 0.000), TG (r= 0.195, P= 0.017)
and LDL-C (r= 0.309, P= 0.000); and CETP were positively
correlated with number of vessel disease (r = 0.238,
P = 0.013), Gensini score (r= 0.282, P= 0.002), TC (r= 0.209,
P= 0.016) and LDL-C (r= 0.202, P= 0.023) (Table 3).








Age (y) 64.52 ± 12.04 67.42 ± 13.34 63.79 ± 13.17
Male/female 62/26 56/23 64/21
Hypertension (%) 59 (67%) 62 (78%) 0 (0)
Ischemic stroke (%) 32 (36%) 24 (30%) 0 (0)
Diabetes mellitus (%) 39 (44%) 30 (38%) 0 (0)
Medication
Statins, n (%) 48 (54.5) 25 (31.6) 0 (0)
ACEI/ARB, n (%) 63 (71.6) 51 (64.6) 0 (0)
Beta blockers, n (%) 58 (65.9) 42 (53.2) 0 (0)
Aspirin (%) 60 (68.2) 26.2 (21.0) 0 (0)
Angiographic analysis
Maximal stenosis (%) 89.34 ± 15.62** 23.87 -
Number of vessel
disease
2.04 ± 0.85 1.14 ± 0.93 -
cTnI, ng/L 19.42 ± 71.19** 0.03 ± 0.02 -
CK-MB, U/L 75.42 ± 126.14** 11.68 ± 4.12
Gensini score 62.23 ± 41.58** 17.20 ± 18.39 -
Data are presented as the mean ± SD or number (%) of subjects
Compared with SCAD: *P < 0.05, **P < 0.01
Table 2 Plasma preβ1-HDL, CETP and other lipid concentrations







TC(mmol/L) 4.68 ± 1.34 4.16 ± 1.10 4.62 ± 0.58
TG(mmol/L) 2.04 ± 1.47** 1.70 ± 1.31** 1.09 ± 0.41
HDL-C(mmol/L) 0.99 ± 0.23** 1.13 ± 0.72** 1.31 ± 0.25
LDL-C(mmol/L) 2.91 ± 1.02* 2.88 ± 0.85* 2.45 ± 0.81
Preβ1-HDL(μg/L) 36.24 ± 17.03**,# 24.68 ± 21.02** 7.44 ± 5.49
CETP (mg/L) 3.42 ± 1.80**,## 2.05 ± 1.10* 1.52 ± 0.98
Compared with control: *P < 0.05; **P < 0.01
Compared with SCAD: #P < 0.05; ##P < 0.01
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To further explore the possible factors affecting preβ1-
HDL levels in CAD patients, the multiple linear regres-
sion analyses was performed. Consequently, the TC,
CETP accounted for 19.9% of the variation of preβ1-
HDL levels, when all variables that were significantly
correlated with preβ1-HDLwere included as independent
variables (Table 4).
Preβ1-HDL and CETP as risk factors for ACS and SCAD
The univariate and multivariate logistic regression ana-
lyses were next performed to evaluate the possible associa-
tions of preβ1-HDL and CETP with CAD. As shown in
Table 5, using the control group as the reference category
when the ACS, SCAD or control group was treated as a
dependent three-category variable, the univariate analyses
revealed that increased preβ1-HDL or CETP was the
potential risk factor for ACS (preβ1-HDL, OR = 1.161,
95% CI: 1.107–1.219, P < 0.001; CETP, OR = 3.055, 95%
CI: 2.158–4.326, P < 0.001), and for SCAD (preβ1-
HDL, OR1.142, 95% CI: 1.089–1.198, P < 0.001; CETP,
OR = 1.632, 95% CI: 1.188–2.217, P < 0.05). To further
evaluate the associations of preβ1-HDL and CETP with
the severity of CAD in ACS or SCAD patients, preβ1-
HDL (OR = 1.017, 95% CI: 1.003–1.031, P = 0.016) and
CETP (OR = 1.931, 95%CI: 1.456–2.563, P < 0.001)
were found closely associated with ACS group when
treated the SCAD group as the reference category.
After adjusting for age, gender and plasma lipid levels
and using the control group as the reference category,
when the ACS, SCAD or control group was treated as a
dependent three-category variable, the increased
preβ1-HDL or CETP was also revealed to be the poten-
tial risk factor for both ACS (preβ1-HDL, OR =1.236,
95% CI: 1.118–1.366, P < 0.001; CETP, OR = 3.077, 95%
CI: 1.765–5.364, P < 0.001) and SCAD (preβ1-HDL,
OR = 1.207, 95% CI: 1.094–1.332, P < 0.001; CETP,
OR = 1.866, 95% CI: 1.105–3.152, P = 0.020). Similarly,
preβ1-HDL or CETP was also showed closely associ-
ation with ACS group when treated the SCAD group
as the reference category.
Discussion
This study for the first time shows that the elevated
preβ1-HDL levels were related to the presence and se-
verity of CAD and changed with CETP levels in CAD
patients. Compared with control subjects, the plasma
levels of preβ1-HDL and CETP were significantly in-
creased in both SCAD and ACS patients. CETP was
Table 3 Spearman rank correlations between preβ1-HDL, CETP
and other variable in CAD patients
Variable Preβ1-HDL CETP
TC 0.401**(P = 0.000) 0.209*(P = 0.016)
TG 0.195*(P = 0.017) 0.126 (P = 0.150)
HDL-C 0.052 (P = 0.537) −0.0335 (P = 0.692)
LDL-C 0.309** (P = 0.000) 0.202*(P = 0.023)
CETP 0.348**(P = 0.000) -
Preβ1-HDL - 0.348**(P = 0.000)
Maximal stenosis(%) 0.253** (P = 0.005) 0.087(P = 0.370)
Number of vessel disease 0.274** (P = 0.002) 0.238*(P = 0.013)
Gensini score 0.227** (P = 0.009) 0.282** (P = 0.002)
*P < 0.05; **P < 0.01
Table 4 Stepwise multiple linear regression analyses of factors





Independent variables in the model
Constant
TC 8.448 1.917 0.371 0.000
CETPa 2.706 1.216 0.187 0.028
Independent variables excluded from model
TGa 0.086 0.354
LDL-Ca −0.045 0.743
The dependent variable was preβ1-HDL (adjusted R2 = 0.199). TC, TG, LDL-C,
Ox-LDL and CETP were used for independent variables
aThese variables were log-transformed before analyses
Table 5 Logistic regression analysis of risk factors for ACS and
SCAD
Preβ1-HDL CETP
OR(95%CI) P value OR(95%CI) P value
Univariate analysesa,b
Model1
ACS 1.161 (1.107–1.219) <0.001 3.055 (2.158–4.326) <0.001
SCAD 1.142 (1.089–1.198) <0.001 1.623 (1.188–2.217) 0.002
Model2
ACS 1.017 (1.003–1.031) 0.016 1.931 (1.456–2.563) <0.001
Multivariate analysesa,c
Model1
ACS 1.236 (1.118–1.366) <0.001 3.077 (1.765–5.364) <0.001
SCAD 1.207 (1.094–1.332) <0.001 1.866 (1.105–3.152) 0.02
Model2
ACS 1.024 (1.002–1.046) 0.031 1.682 (1.221–2.318) 0.001
Model1 : the reference category was the control group
Model2 : the reference category was the SCAD group
aIn univariate and multivariate logistic regression analyses, the ACS, SCAD or
control group was treated as a dependent three-category variable and the OR
was considered statistically significant when the lower limit of the 95% CI
was > 1.0 and the P-value was < 0.05
bOnly one of Preβ1-HDL, CETP was included in the univariate analyses
cThe age, gender and coexisting conditions were adjusted in the
multivariate analyses
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found to be one of potential predictors for preβ1-HDL
levels. Furthermore, the preβ1-HDL levels in ACS
patients were significantly higher than those in SCAD
patients, and were significant risk for both ACS and
SCAD patients.
Preβ1-HDL has been reported to be increased in
CAD patients [10]. Amar et al. found that preβ1-HDL
concentrations were 2-fold higher in individuals with
ischemic heart disease (IHD) than no IHD groups [22].
Besides, it has been reported that preβ1-HDL level was
markedly higher in the unstable angina pectoris (UAP)
subgroup than in the stable angina pectoris (SAP) sub-
group [23, 24]. In this study, we found that the preβ1-
HDL levels increased in CAD patients and it’s levels in
ACS patients were significantly higher than those in
SCAD patients, which was consistent with earlier ob-
servations [23, 24] suggesting that the increased preβ1-
HDL concentrations might be one of the major factors
for the occurrence and severity of CAD. In addition, we
further found that plasma preβ1-HDL was positively re-
lated with degree of coronary artery stenosis, number
of vessel disease and Gensini score, suggesting that the
increased preβ1-HDL may associated with cholesterol
accumulation in coronary artery vessels. Miyazaki et al.
[25] and Sethi et al. [22] also found that the preβ1-HDL
level was high in hyperlipidemic and ischemic heart
disease subjects. In our and the above studies, preβ1-
HDL level was measured by ELISA using anti-human
preβ1-HDL monoclonal antibody (MAb 55201) specif-
ically reacted with apoA-I associated with preβ1-HDL
in plasma. Recently, Chen et al. described that serum
preβ1-HDL levels were decreased and negatively associ-
ated with Gensini score in patients with coronary artery
diseases [11], which was inconsistent with the above
and previous studies [10, 23, 24]. Chen et al. isolated
the preβ1-HDL using a native polyacrylamide gel elec-
trophoresis (PAGE) system with polyclonal anti-human
apoA-I and detected the levels of preβ1-HDL by densi-
tometry, which is a semi-quantitative method. Whereas,
ELISA is a quantitative method. Although significantly
high preβ1-HDL levels were observed in CAD cases,
the association between preβ1-HDL level and CAD
prevalence was inconsistent. Bela et al. reported that
the increased preβ1-HDL was not significantly associ-
ated with CAD prevalence but associated with recur-
rent CAD events [26, 27]. A large well-characterized
clinical cohort study confirmed the association between
increased levels of preβ1-HDL and risk of CAD, and
proposed that high levels of preβ1-HDL remained a sig-
nificant predictor of CAD even after adjustment for
traditional risk factors [10].
Preβ1-HDL is considered to be an atherogenic lipo-
protein; although Lynnda et al. found that preβ-HDL
formation was affected by high-normal free thyroxine
in type 2 diabetes mellitus [28]. The mechanisms by
which it contributes to atherosclerosis remain widely
unknown. It is important to realize that the RCT path-
way is a cyclical way [10, 29, 30]. The increase of
preβ1-HDL may be indicative of a defect in one part of
the pathway. It has been reported that the causes of in-
creased preβ1-HDL included the defect of ABCA1
transporter, low levels of LCAT, overexpression of
phospholipid transfer protein (PLTP) or increased
plasma cholesterol efflux capacity from macrophages
[3, 31–33]. Increasing evidence suggested that the con-
centration and composition of plasma lipids and lipo-
proteins were markedly affected by the acute phase
reactions, which associated with injury, inflammation
or sepsis [34]. The changes of the concentration and
composition of plasma HDL in patients with ACS could
be secondary to systemic acute phase response. As an
acute phase protein mainly produced in the liver, levels
of serum amyloid A (SAA) both in plasma and HDL
compositions increase markedly in inflammation [34].
It has been suggested that these changes in HDL apo-
protein pattern could increase HDL catabolism, impair
reverse cholesterol transport. This would reverse the
flux of cholesterol between macrophages and HDL and
result in increased macrophage uptake. Therefore, the
changes of the composition of plasma HDL in patients
with ACS that secondary to systemic acute phase re-
sponse were proinflammatory. Preβ1-HDL, as a minor
HDL, may be secondary to systemic acute phase re-
sponse in ACS [35]. Future research should focus on
the role of preβ1-HDL in this process.
Several lines of evidence suggested that preβ1-HDL
concentration associated with CETP level [36]. When
plasma was incubated with exogenous CETP at 37 °C,
total preβ1-HDL concentration increased [37]. In
cholesterol-fed rabbits, serum preβ1-HDL concentra-
tion and CETP activity were 32 and 33% higher than
those in control rabbits respectively [38]. And the
plasma preβ1-HDL concentration was positively corre-
lated with the hepatic CETP mRNA level [38]. In a hu-
man study, probucol increased CETP mass by 20%, and
maintained a high preβ1-HDL concentration in hyper-
cholesterolemics [39]. However, Nicholls et al. found
that evacetrapib, potent CETP inhibitor significantly in-
creased preβ1-HDL levels in dyslipidemic patients [40].
Our present results further confirmed that the plasma
preβ1-HDL levels elevated with high CETP mass in pa-
tients with CAD. As we all known, CETP plays an im-
portant role in the transfer and exchange of CE and TG
among lipoproteins, so that it affects lipid composition,
concentration, particle size and function of lipoprotein
[12]. In addition, it is now accepted that virtually all of
the efflux mediated by the ABCA1 transporter goes to
preβ1-HDL, which contains only one molecular species
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of protein, apoA-I. Then their unesterified cholesterol
is esterified by the action of LCAT, and subsumed into
larger cholesteryl ester-rich HDL particles from which
the esters can be transferred to acceptor lipoproteins,
including VLDL and LDL, mediated by CETP. Thus,
the present results indicated that in CAD patients, with
the increasing CETP concentration, more preβ1-HDL
were regenerated during the CETP-mediated transfer
process. The current study supports the concept that
incubation of large α-HDL particles with CETP may
produce preβ1-HDL, and increased preβ1-HDL may
be an indicator in the reverse cholesterol transport
pathway, which may be closely related to the presence
of CAD.
The limitations of this study include the fact that the
control subjects were not examined by coronary angiog-
raphy to exclude potential CAD. This is mainly limited
by the wishes of the individual volunteers; however, we
have performed physical, electrocardiography and la-
boratory tests for the control subjects and make sure
that all of the controls are without diseases such as
hyperlipidemia, hypertension, diabetes mellitus, or any
clinical sign of atherosclerosis. In addition, subjects
using statin were not excluded from the present study,
fortunately, statin treatment decreases preβ1-HDL so
that it can reveal better the increase of preβ1-HDL in
CAD [40, 41]. Besides, future studies should directly
capture and analyze the embolized debris for preβ1-
HDL and CETP.
Conclusions
The present study demonstrated that elevated plasma
concentrations of preβ1-HDL reflect the presence and
extent of angiographically documented CAD, especially
clinically expressed in ACS. The plasma preβ1-HDL
levels were potently correlated with CETP in CAD, and
may change with CETP concentrations. These finding
will contribute to the understanding of the pathogen-
etic role of preβ1-HDL and CETP in CAD. Further
studies are needed to validate these associations and to
elucidate pathophysiologic mechanisms of plasma
preβ1-HDL in CAD.
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